
Chinook Therapeutics KDNY
Chinook Therapeutics Total Shareholders Equity | KDNY
Annual Total Shareholders Equity Chinook Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 442 M | 454 M | 335 M | -41.1 M | -681 K | 237 M | 227 M | 262 M | -61.3 M | -38.8 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 454 M | -61.3 M | 181 M |
Quarterly Total Shareholders Equity Chinook Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 357 M | 412 M | 442 M | 475 M | 507 M | 427 M | 454 M | 270 M | 297 M | 301 M | 335 M | -72.2 M | -53.8 M | -46.4 M | -41.1 M | 82 M | 101 M | 115 M | -681 K | 158 M | 176 M | 197 M | 237 M | 256 M | 258 M | 229 M | 227 M | 250 M | 246 M | 240 M | 262 M | 243 M | 241 M | -77.3 M | -61.3 M | -61.3 M | -61.3 M | -61.3 M | -38.8 M | - | - | - | -27.7 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 507 M | -77.3 M | 180 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
212 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
63.9 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
3.24 B | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
7.16 M | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
15.8 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
21.5 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
154 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
27.3 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
98.7 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
57.4 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
928 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-473 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
11.8 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
205 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
8.15 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
46.8 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
156 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
15.1 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
163 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-4.08 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-914 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-8.44 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-45.3 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
6.12 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-31.5 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
31.8 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
44.6 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-11.9 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
39.1 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
76.4 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
149 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
992 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
22.7 B | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
207 M | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | ||
|
Turning Point Therapeutics
TPTX
|
954 M | - | -0.13 % | $ 3.73 B | ||
|
Orgenesis
ORGS
|
-37.5 M | - | -33.86 % | $ 61.2 M | ||
|
TCR2 Therapeutics
TCRR
|
141 M | - | - | $ 58.1 M |